All Trials

A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic gastric/GEJ adenocarcinoma that is HER2-negative, CLDN18.2-positive, and PD-L1–positive (ECOG 0–1) are randomized to pembrolizumab plus CAPOX or mFOLFOX6 with either zolbetuximab or placebo. Zolbetuximab is a CLDN18.2-targeted IgG1 monoclonal antibody that mediates ADCC/CDC; key exclusions include prior metastatic-line therapy (beyond one initial dose), active autoimmune disease, immune pneumonitis, CNS mets, significant GI obstruction/bleeding, and >grade 1 neuropathy.

ClinicalTrials.gov ID: NCT06901531

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Newly diagnosed, unresectable/metastatic, SSTR-positive, well-differentiated G1–G2 (Ki-67 &lt;10%) advanced GEP-NETs with high disease burden (adolescents/adults, ECOG 0–1) randomized to [177Lu]Lu-DOTA-TATE plus octreotide LAR versus octreotide LAR alone. [177Lu]Lu-DOTA-TATE is a somatostatin receptor–targeted peptide receptor radionuclide therapy delivering beta-emitting 177Lu via DOTA-TATE to SSTR2-expressing tumors.

ClinicalTrials.gov ID: NCT06784752

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with locally advanced/metastatic solid tumors—emphasizing urothelial carcinoma—harboring actionable FGFR3 alterations receive the selective FGFR3 inhibitor LOXO-435 (LY3866288) as monotherapy or combined with pembrolizumab ± enfortumab vedotin. Cohorts include FGFR inhibitor–naïve, post–FGFR inhibitor, and first-line mUC settings; key exclusions include uncontrolled CNS disease and significant ocular/cardiac risks.

ClinicalTrials.gov ID: NCT05614739

A Phase II Trial to Evaluate Pemetrexed Response in Relation to Tumor Alterations of Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma and Other Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic urothelial carcinoma or other solid tumors harboring loss-of-function alterations in KMT2D (MLL4), KDM6A (UTX), or MTAP receive pemetrexed every 21 days with standard vitamin/steroid supplementation. Pemetrexed is an antifolate chemotherapy inhibiting TS, DHFR, and GARFT, tested here in genomically selected tumors potentially sensitized via one‑carbon metabolism or PRMT5/MTAP axis vulnerabilities.

ClinicalTrials.gov ID: NCT06630416

CAST-AI: Cystectomy After Systemic Therapy With ADC and Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed, node-positive or metastatic urothelial carcinoma (bladder or upper tract), ECOG 0–2, receive first-line enfortumab vedotin (nectin‑4–targeting MMAE ADC) plus pembrolizumab (PD‑1 inhibitor) for at least 4 cycles, then proceed to cytoreductive cystectomy and/or ureterectomy if surgical candidates, with optional metastasis-directed therapy and potential postoperative maintenance EV/pembrolizumab. Excludes prior systemic therapy or checkpoint inhibitor exposure, significant comorbidities/autoimmunity, and prior pelvic RT.

ClinicalTrials.gov ID: NCT06764095

Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic bladder cancers of variant or non-urothelial epithelial histologies (e.g., micropapillary, plasmacytoid, sarcomatoid, squamous, adenocarcinoma/urachal), ECOG 0–1, treatment-naïve or previously treated, excluding prior EV or PD-1/L1 therapy. Treatment is enfortumab vedotin (Nectin-4–targeting antibody–drug conjugate delivering MMAE) plus pembrolizumab (PD-1 inhibitor).

ClinicalTrials.gov ID: NCT05756569

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with oligometastatic clear cell RCC (≤5 measurable lesions; ECOG 0–1) receive definitive radiation to all treatable sites and are randomized to 1 year of maintenance pembrolizumab vs observation. Pembrolizumab is an anti–PD-1 antibody immunotherapy; brain metastases allowed, prior recent immunotherapy and significant immunosuppression excluded.

ClinicalTrials.gov ID: NCT06004336

A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-pretreated Metastatic Clear Cell Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic clear cell RCC who have progressed after 2–3 prior lines including a PD-1/PD-L1 inhibitor and a VEGFR TKI receive oral abemaciclib (CDK4/6 inhibitor) plus cabozantinib (multikinase inhibitor targeting MET/VEGFR2/AXL). Single-arm study assesses safety/MTD and preliminary efficacy; excludes prior abemaciclib/cabozantinib and patients with uncontrolled CNS disease, significant CV risk, or strong CYP3A modulator use.

ClinicalTrials.gov ID: NCT06835972

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Treatment‑naïve adults with locally advanced or metastatic clear‑cell RCC (ECOG 0–1), including those with controlled, non–life‑threatening brain metastases, receive triplet therapy with 177Lu‑girentuximab (TLX250; CAIX‑targeted radiolabeled mAb delivering beta radiation), nivolumab (PD‑1 inhibitor), and cabozantinib (VEGFR/MET/AXL TKI). Key exclusions include prior systemic therapy for metastatic RCC, active autoimmune disease requiring therapy, recent major cardiovascular events, significant GI/fistula risk, uncontrolled hypertension, strong CYP3A4 modulators, and recent major surgery.

ClinicalTrials.gov ID: NCT05663710

Phase I/II Trial of Inulin Gel in Combination With Ipilimumab and Nivolumab in Advanced Renal Cell Carcinoma [ICON Trial]

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with untreated metastatic or progressive locally advanced clear cell/sarcomatoid RCC (ECOG ≤2) are randomized to standard ipilimumab plus nivolumab versus the same regimen plus oral inulin gel, a fermentable prebiotic fiber intended to modulate the gut microbiome to enhance checkpoint inhibitor response. Key exclusions include active/unstable brain mets, significant GI disease/surgery, recent antibiotics/probiotics, and autoimmune conditions requiring immunosuppression.

ClinicalTrials.gov ID: NCT06866262